BioSpace News Archive

Increasing preference for safe and accurate drug delivery systems, technological advancements in drug infusion systems, and seamless integration of drug infusion systems with electronic health records are some key factors expected to drive market growth.

The global biotechnology market size is expected to be worth around US$ 3.44 trillion by 2030 from valued at US$ 852.88 billion in 2020 and is anticipated to grow at a CAGR of 17.83% during forecast period 2021 to 2030.

According to Report, the global sinus dilation device market size is expected to surpass around US$ 8.6 billion by 2030 from valued at US$ 2.7 billion in 2020 and expanding growth at a CAGR of 15% from 2021 to 2030.

The U.S. Food and Drug Administration expanded the approval of the COVID-19 treatment Veklury to include pediatric patients 28 days of age and older weighing at least 3 kilograms with positive results of direct SARS-CoV-2 viral testing.

TeDan Surgical Innovations, leader in the development and commercialization of surgical access systems continues to address evolving surgical access techniques to the spine through the market release of the Phantom UL™ Anterior to the Psoas Surgical Access System.

Chinook Therapeutics, Inc. announced that Chinook management is scheduled to present and participate in 1x1 meetings at the 2022 Bloom Burton & Co. Healthcare Investor Conference in Toronto, Ontario on Monday, May 2, 2022 at 10:00 am ET.

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced that it has commenced a proposed underwritten public offering to issue and sell $150 million of shares of its common stock.

Cognition Therapeutics, Inc. (NASDAQ: CGTX), will be presenting a poster at the annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) summarizing preclinical results showing that sigma-2 (σ-2) receptor modulators protect RPE cells and normalize key homeostatic processes disrupted in dry age-related macular degeneration (dry AMD).

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) reached an agreement with BeiGene (Beijing) Co., Ltd. (“BeiGene”) (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen’s fully human antibody RenMab™/RenLite™ mice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs.

Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2022.